Credit Suisse’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Credit Suisse’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$541K	Buy	+25,034	New	+$546K	﹤0.01%	2605

Other funds holding LBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Credit Suisse's LBPH Position: Q1 2024 in Review

Credit Suisse opened a new position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q1 2024: 25,034 shares worth $541K. The stake represents ﹤0.01% of the portfolio and ranks #2605 among its holdings.

105 funds tracked by Wall St. Rank hold LBPH as of Q1 2024.

Credit Suisse held 25,034 shares of Longboard Pharmaceuticals, Inc. Common Stock worth $541K as of Q1 2024.
Longboard Pharmaceuticals, Inc. Common Stock was a new Credit Suisse position in Q1 2024.
Longboard Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2605 holding.
105 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.